News After a long biotech IPO lull, LB Pharma chances its arm After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.
News BridgeBio’s $250m raise heads latest biotech financings BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloido
News Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.